A cadre of researchers, academics, insurers and patient advocates are calling for major reform in how tumor biomarker tests are regulated, reimbursed and developed. They argue that the current system leaves the diagnostic tools chronically underused and holds back the advance of personalized cancer care.
To effectively target cancer or autoimmune disease cells without causing too much harm to healthy ones in the process, researchers are turning to molecular "robots," small DNA-based platforms with binding sites highly specified to interact solely with disease-causing populations.
Life Technologies brings newly acquired biomarker expertise to its companion diagnostics collaboration deal with Merck Serono, putting into play technology it snatched up last October.
The iKnife device, developed by Budapest-based MediMass, has wowed researchers in early testing, and now the Budapest company's CEO says he's close to partnering with a larger med tech operation in the hopes of bringing the product to market.
Rexahn Pharmaceuticals signed an exclusive license agreement of an undisclosed amount with the University of Maryland in Baltimore for a novel cancer-drug delivery platform that makes use of nanotechnology.
German genomics contractor Blackfield locked up a deal with AstraZeneca, agreeing to provide its computational biology technology to help the drugmaker validate an in-development cancer therapy.
Delcath Systems, hamstrung by an unforgiving FDA review of its cancer-treating device, plans to slash its payroll by about 20% to reduce the company's expenses.
Massachusetts' Mevion Medical has hauled in another $55 million to help commercialize its proton-therapy system for cancer, a device the company touts as smaller and more reliable than its competitors.
Thanks to some big-name deals over the past year, Ambrx could rake in nearly $1 billion in licensing for its antibody drug conjugates, but the company hasn't lost sight of its in-house development, now partnering with WuXi PharmaTech and a Chinese drugmaker to advance a breast cancer treatment.
Gold nanoparticles, because of several inherent characteristics, make excellent drug delivery vehicles, and scientists around the world are now studying the way the tiny particles penetrate cell membranes based on their positive or negative surface charges.